Transporting eating architecture

For my thesis, I worked on transporting, or perhaps translating, the lavash practice. An Armenian flatbread cooked in a tonir •. A hearth symbolizing the sun in the ground. My disciplinary positioning is one of conservation and preservation. I looked at the practice of Lavash at three horizontal levels: The land, the refectory and the table. Each of these levels informed me on where and how I would be transporting the practice. The village women, when making lavash, were living next to the field where the wheat is grown and harvested. They were using stone mills, which allowed the grain to be grind at a low temperature. This guaranteed freshness and preserved the grains’ all nutrients. I also looked at the Haghartsin monastery in the Tavush region of Armenia because it had a refectory next to a bakery and a big stone mill. Again, the bread was consumed in proximity to where the grain was harvested, milled and the dough was baked. These analysis lead me to choose a site that would allow me to plant and harvest the wheat. A site that would include big stone mill(s) and a place/silos where grain could be stored. My proposal’s objective mainly allows people to observe and understand the practice, to participate in the making and consuming of Lavash. Ultimately it would be a site for human interaction and gathering through a practice

Perceptions of Coding Instruction in K-12 Archdiocese of Los Angeles Catholic Schools

Traditional pedagogy offers students opportunities to enhance various skills and acquire content knowledge; however, additional steps can be taken to enhance student achievement, prepare them for future occupations, and bridge the divide in access to technology. A curriculum that integrates coding instruction affords students the opportunity to augment their collaboration, communication, creative thinking, and problem-solving skills. This is especially crucial for traditionally marginalized populations who have experienced inequitable access to technology. Nevertheless, coding is not integrated in schools in different domains, including Catholic institutions in the Archdiocese of Los Angeles (ADLA). This dissertation used a descriptive and inferential quantitative methodology to survey K–12 Catholic school teachers’, administrators’, and STEM directors’ understanding of what coding entails, assess their perceptions of coding’s potential to enrich student achievement, to prepare them for future occupations, and diversify STEM representation both in academics and in the workplace, and evaluate the potential link between educator epistemology and pedagogy with the penchant to incorporate coding instruction and the constructionist framework in the classroom. The largest diocese of the country, the ADLA, was the sole focus of this study and the data demonstrated participants have a relatively limited understanding of what coding entails, but they do believe it results in various benefits for students. Nevertheless, their epistemology and pedagogy are not ripe for constructionism to take hold in the classroom to facilitate coding

Momelotinib in myelofibrosis patients with thrombocytopenia: Post hoc analysis from three randomized phase 3 trials

The oral activin A receptor type I, Janus kinase 1 (JAK1), and JAK2 inhibitor momelotinib demonstrated symptom, spleen, and anemia benefits in intermediate- and high-risk myelofibrosis (MF). Post hoc analyses herein evaluated the efficacy and safety of momelotinib in patients with MF and thrombocytopenia (platelet counts \u3c100 × 1

ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis

Acknowledgments: The authors would like to thank Dominique Gien, Sirandou Tounkara, and Eliane Véra at Centre National de Référence pour les Groupes Sanguins for the management of blood samples. Funding: The work was supported by Institut National de la Santé et de la Recherche Médicale (Inserm), Institut National de la Transfusion Sanguine (INTS), the University of Paris, and grants from Laboratory of Excellence (Labex) GR-Ex, reference No. ANR-11-LABX-0051. The Labex GR-Ex is funded by the IdEx program “Investissements d’avenir” of the French National Research Agency, reference No. ANR-18-IDEX-0001. R.B. was funded by the European Union’s Horizon 2020 Research and Innovation Program under grant agreement No. 675115-RELEVANCE-H2020-MSCA-ITN-2015. M.B. was funded by Ministère de l’Enseignement Supérieur et de la Recherche at the BioSPC Doctoral School. R.B. and M.B. also received financial support from Société Française d’Hématologie (SFH) and Club du Globule Rouge et du Fer (CGRF).Peer reviewedPublisher PD

Altered Ca2+ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis

The authors thank Thierry Peyrard, Dominique Gien, Sirandou Tounkara, and Eliane Véra at Centre National de Référence pour les Groupes Sanguins for the management of blood samples. The authors thank Sandrine Genetet and Isabelle Mouro-Chanteloup at the Inserm UMR_S1134 unit for their assistance in experiments. The authors also thank Michaël Dussiot at the Institute Imagine for his assistance in imaging flow cytometry. We thank Johanna Bruce and Virginie Salnot at 3P5 Proteomics Platform for sample preparation and analysis, and François Guillonneau and Patrick Mayeux for their management and strategies. Funding: The work was supported by Institut National de la Santé et de la Recherche Médicale (Inserm); Institut National de la Transfusion Sanguine (INTS); the University of Paris; and grants from Laboratory of Excellence (Labex) GR-Ex, reference No. ANR-11-LABX-0051. The Labex GR- Ex is funded by the IdEx program “Investissements d’avenir” of the French National Research Agency, reference No. ANR-11-IDEX-0005-02 and ANR-18-IDEX-0001. R.B., M.G.R., and D.M.A. were funded by the European Union’s Horizon 2020 Research and Innovation Program under grant agreement No. 675115-RELEVANCE-H2020-MSCA-ITN-2015. R.B. also received financial support from Société Française d’Hématologie (SFH) and Club du Globule Rouge et du Fer (CGRF). R.B. is currently funded by the Innovate UK Research and Innovation Knowledge Transfer Partnership (KTP) between University of Aberdeen and Vertebrate Antibodies Ltd. (Partnership No. KTP12327). T.D. was supported by PhD grants from Université Paris Saclay MESR (Ministère Enseignement Supérieur et de la Recherche) and then FRM (Fondation recherche médicale). The Orbitrap Fusion mass spectrometer was acquired with funds from Fonds Europeen de Developpement Regional (FEDER) through the Operational Program for Competitiveness Factors and Employment 2007-2013 and from the Canceropole Ile de France.Peer reviewedPublisher PD

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

Thrombocytopenia is common in patients with myelofibrosis (MF) and is a well-established adverse prognostic factor. Both of the approved Janus kinase (JAK) inhibitors, ruxolitinib and fedratinib, can worsen thrombocytopenia and have not been evaluated in patients with severe thrombocytopenia (platelet counts \u3c50×109/L). Pacritinib, a novel JAK2/interleukin-1 receptor-associated kinase 1 inhibitor, has been studied in two phase III trials (PERSIST-1 and PERSIST- 2), both of which enrolled patients with MF and severe thrombocytopenia. In order to better characterize treatment outcomes for this population with advanced disease, we present a retrospective analysis of efficacy and safety data in the 189 patients with severe thrombocytopenia treated in the PERSIST studies. The proportion of patients in the pacritinib group meeting efficacy endpoints was greater than in the BAT group for ≥35% spleen volume reduction (23% vs. 2%, P=0.0007), ≥50% modified Total Symptom Score reduction (25% vs. 8%, P=0.044), and self-reported symptom benefit ( much or very much improved; 25% vs. 8%, P=0.016) at the primary analysis time point (week 24). The adverse event profile of pacritinib was manageable, and dose modification was rarely required. There was no excess in bleeding or death in pacritinib-treated patients. These results indicate that pacritinib is a promising treatment for patients with MF who lack safe and effective therapeutic options due to severe thrombocytopenia